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needed to increase the cure rate. In vitro experiments show
strong antiviral effects of ﬂuvastatin against HCV.
Aim of the study: To asses the clinical outcome of ﬂuvastatin
addition to the standard regimen for treatment of chronic
HCV in Egypt.
Subjects and Methods: The study included 80 patients
with chronic hepatitis C virus infection fulﬁlled clinical,
laboratory and histo-pathological criteria to be ready for
interferon therapy, divided into two groups: Group I (n = 40)
received standard treatment for HCV (pegylated interferon
and ribavirin) and group II (n = 40) received standard
treatment plus ﬂuvastatin (80mg/daily). Before and after
6 months of treatment liver function tests and HCV-RNA
were evaluated.
Results: Addition of ﬂuvastatin to the standard HCV
treatment (pegylated interferon and ribavirin) signiﬁcantly
increased SVR from (55% to 62.5%; P< 0.01) and signiﬁcantly
decreased viral load in relapser patients (P< 0.001). No
signiﬁcant differences and correlations were found between
serum levels of LDL-cholesterol and viral load before and
after treatment in both groups.
Conclusion: Fluvastatin can be used to increase SVR when
added to standard treatment (pegylated interferon and
ribavirin) of chronic HCV.
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Background: We have found 70% response rate in Pakistan
for Genotype-3a patients with combinationtherapy of
interferon and ribavirin. There is need to individualize the
treatment to minimize the side effects.
Methods: For the current study ﬁve G3 patients,
nonresponder of 24 weeks interferon-alpha-2b plus ribivirin
therapy, withalmost equal levels of viremia (1.8×107
IU/ml) at the end of treatmentwere selected. Mean
viral load at week 36 was 2.6×106 IU/ml, atweek 48
raised to 2.0×107 IU/ml. All samples were quantiﬁed on
RotorGene3000™. Interferon sensitivity-determining region
(ISDR) innon-structural region-5A was studied to link any
genetic changes in virus genomewith therapy esistance.
ISDR was ampliﬁed using genotype 3aspeciﬁc ISDR primers
followed by sequencing and bioinformatics tools.
Result: A157bp ISDR product corresponding to 52 aminoacid
protein, when compared with responderHCV patient naïve
genome [Table 1], eight amino acid mutations were
detected includingdeletions and substitutions affecting the
molecular weight of protein. Gly, Trp, Pro, Leu. His,
Thr were substituted by Arg, Gln, Ala, Pro, Pro, Ala
respectively.
Conclusion: Mutations in ISDR region may have role in
virus-resistance and high viremia, inﬂuencingthe therapy
response. Screening will help in deciding treatment plan
makingit cost-effective.
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Objectives: Our aim was to identify the prevalence of
hepatitis C virus (HCV) genotype and investigate genetic
mutation of HCV 5′ non-coding region (5′NCR) sequences in
Shandong province of China.
Methods: Serum samples from 118 chronic hepatitis C
patients hospitalized in Jinan Infectious Disease hospital
were collected. Serum samples were ampliﬁed from 5′NCR
by RT-PCR and PCR products were sequenced by Sangon
Biotech (Shanghai) Co., Ltd. Sequences of 5′NCR of the
patients were compared with reference HCV strains from
Genebank and phylogenetic tree analysis was performed.
Results: The cases among genotype 1b, 2a, 1a, 3a, 3b, 6a
were 65 (55.1%), 45 (38.1%), 2, 1, 2 and 3, respectively.
Sequences of 5′NCR in 42 genotype 1b patients were
identical. Compared to reference HCV 1b strains, 23
genotype 1b patients have 1 2 bases mutation with two
characteristic nucleotide mutation sites (120 C-T and 204
C-T). The homology of 5′NCR among genotype 2a patients
was 97.8%-100% with characteristic nucleotide mutation
sites (site 222 C-T and 247 C-T). The homology of genotype
1a, 3a, 3b and 6a with the same genotype HCV stains from
Genebank was high, only with 1 3 bases mutation.
Conclusions: The predominant genotype of chronic
hepatitis C patients in Shandong province is 1b, followed
by 2a and a small amount of 1a, 3a, 3b, 6a. Genotype 3a
and 6a are not reported before. Sequence of HCV 5′NCR is
highly conservative and accords to HCV strains worldwide.
Both genotype 1b and 2a have characteristic nucleotide
mutations.
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Background: Development of HCV infection is typically
followed by chronic hepatitis C (CHC) in most patients,
while spontaneous HCV viral clearance (SVC) occurs in only
a minority of subjects. With the development of techniques
for direct detection of the HCV virus (RNA or core protein), it
is expected that HCV infectious status can be evaluated bet-
ter if the results of HCV antibodies and virus detection were
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considered together. Compared with the widespread appli-
cation of HCV RNA test by quantitative RT-PCR technique,
HCV core antigen detection may be an alternative indicator
in the diagnosis of hepatitis C virus infections and in moni-
toring the status of infectious individuals. However, the ap-
plication and signiﬁcance of HCV core antigen assay and its
correlation with HCV RNA detection are still not well inves-
tigated, especially on the background of HIV coinfection.
Methods: In this study, we analyzed and compared the
serological and virological characteristics of HCV viremia-
positive and viremia-negative patients in a total of 354 HCV
and/or HIV seropositive subjects enrolled from a village of
central China. Besides HCV-related hepatopathic variables
including clinical status, ALT, AST, anti-HCV Abs, as well as
the altered CD4+/CD8+ T cell counts, HCV core antigen and
HCV viral load were also measured.
Results:
1. The 354 participants were divided into 5 groups
(HIV-noninfected CHC (129/354, 36.44%), HIV-infected
CHC (98/354, 27.68%), HIV-1-noninfected SVC (65/354,
18.36%), HIV-infected SVC (44/354, 12.43%), and HIV
infection (18/354, 5.08%) alone) depending on the
existence of anti-HCV antibody, anti-HIV antibody, and
HCV viral load.
2. No signiﬁcant difference of either ALT (X2 = 0.221,
p = 0.638) or AST (X2 = 0.018, p = 0.895) was found
between the HCV mono-infection (HIV-noninfected CHC,
44.96% for ALT and 44.18% for AST) group and the
HCV/HIV coinfection (HIV-infected CHC, 41.84% for ALT
and 45.92% for AST) group. Interestingly, there were
signiﬁcant differences for ALT (X2 = 3.854, p = 0.05) and
AST (X2 = 13.722, p < 0.001) between the HIV-noninfected
SVC (10.78% for ALT and 3.08% for AST) and the HIV-
infected SVC (25.00% for ALT and 27.08% for AST).
3. 96.90% HIV-noninfected CHC patients and 97.96% HIV-
infected CHC patients were reactive to the HCV core
antigen measurement. And for the ﬁrst time, we
reported that serum concentrations of HCV core antigen
were highly correlated with HCV RNA levels in both HCV
mono-infected (r = 0.8083, p < 0.001) and HCV/HIV co-
infected (r = 0.9524, p < 0.001) patients in this study.
4. HCV core antigen concentration was negatively corre-
lated (r = 0.2847, p = 0.0083) with CD4+ T cell counts
less than 1000/ml, and S/CO ratio of anti-HCV antibody
(r = 0.3155, p = 0.0033) was positively correlated with
CD4+ T cell counts in HIV-infected CHC patients with
CD4+ T cell counts, while no correlation was found
between HCV RNA level and CD4+ T cell count.
Conclusions: In total, our ﬁndings demonstrated that there
were distinctive serological and virological characteristics
of serum HCV RNA positive and negative hepatitis C patients
with or without HIV-1 coinfection. Importantly, there was
an excellent correlation between plasma HCV viral load
and the concentration of HCV core protein not only in the
HCV mono-infected population but also in the HCV/HIV-1
coinfected population. The HCV antigen assay detected
the vast majority of HCV RNA positives with or without
HIV infection. Considering HCV, core antigen testing has a
comparable sensitivity to HCV RNA qPCR. HCV core antigen
concentration, but not HCV RNA level, was negatively
correlated with CD4+ T cell counts. Our data suggested that
quantitative detection of plasma HCV core antigen may be a
better indicator of peripheral HCV level than HCV RNA level
when evaluating the association between HCV replication
and host immune status in HCV/HIV coinfected patients.
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Objectives: To elucidate impact of amino acid (aa)
substitutions of interferon sensitivity determining region
(ISDR) of HCV on the outcome of combined pegylated
interferon/ribavirin therapy in the patients with chronic
hepatitits C virus genotype 1b infection in Southern China.
Methods: A total of 44 patients with chronic HCV 1b
infection who received 48 weeks of combination therapy
and 6-month follow up were analyzed retrospectively.
Clinical and laboratory parameters including gender, age,
route of transmission, ALT, AST, quantiﬁcation of HCV RNA
and the substitution number of ISDR were assessed. The
binary logistic regression analysis to identify those that are
independently associated with the early virological response
(EVR), end of treatment virological response (ETVR) and
sustained virological response (SVR) was conducted.
Results: Sequences of ISDR were compared with HCV
J strain.11 of 44 isolates were wild type, 32 were
intermediate type (2 3 aa substitutions) and only 1 was
mutant type (4 or more aa substitutions). The SVR rate
was 43.2% (19/44). The statistical analysis indicated there
was a signiﬁcant correlation between the aa mutation
number (2) in HCV ISDR and SVR/EVR (P= 0.005/P= 0.018);
and the independent variables related to SVR were the
mutation number in ISDR (OR, 17.038; P= 0.011), age group
(40 years) (OR, 12.259; P= 0.011) and AST (OR, 1.021;
P= 0.020).
Conclusions: These results support the hypothesis of aa
substitution at ISDR of HCV genotype 1b could predict SVR.
Although the aa sequence of ISDR is conservative, and the
mutant type of ISDR (4 or more aa substitutions) is rare in
Southern China, it is interesting that the mutation number
of ISDR as a predictor of SVR can decreased from 4 to 2
when using PEG-IFN plus RBV combination therapy.
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Background: The effective standard therapeutic regimen
using PEG-IFN in combination with RBV has led to improved
sustained viral response rates for patients with chronic
hepatitis C (CHC). However, PEG-IFN is very expensive;
most patients cannot afford the treatment in China. The
recombinant IFN-2b is much cheaper and has been proven
to be safe and effective. The low cost allows to treat a
wide range of patients.
Methods: A total of 264 treatment-naïve patients with
CHC received the treatments of recombinant IFNa-2b (5
MIU/qod) and RBV (900mg/d). The efﬁcacy and safety of
the treatment were investigated and inﬂuencing factors
were evaluated.
